Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
The First Affiliated Hospital of Soochow University
Hol
Suzhou (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
30 fő, tervezett
Kezdés
2025. szept. 1.
Várható befejezés
2027. júl. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Romiplostim N01
  • Rituximab
A regiszteradat frissítve
2025. december 4.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people aged 14 years or older with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. Their disease did not respond well enough to an oral TPO-RA medicine.

Életkor
14 years or older
Nem
All sexes
A betegség stádiuma
Confirmed primary ITP. Platelet count below 30 × 10⁹/L at screening, or below 50 × 10⁹/L with clinically significant bleeding.
Korábbi kezelés
At least one earlier ITP treatment, including at least 4 weeks of an oral TPO-RA (hetrombopag or eltrombopag) that was stopped because it did not work well enough. Glucocorticoid dose must be stable (not more than 4 tablets daily) for at least 2 weeks. Other immunosuppressants must be stable for at least 4 weeks. No intravenous immunoglobulin in the 2 weeks before the first dose. No platelet transfusion in the 1 week before the first dose.

A részvétel fő kizáró okai

  • ITP caused by another condition, such as another autoimmune disease, a viral infection or a drug
  • Active cancer
  • Pregnancy
  • Serious heart or brain blood vessel disease
  • History of blood clots in an artery or vein

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Ki vehet részt

  • Confirmed diagnosis of primary immune thrombocytopenia (ITP)
  • Age ≥14 years
  • Prior exposure to at least one ITP-directed therapy (e.g., corticosteroids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO-RAs, immunosuppressants, or splenectomy), including a minimum 4-week course of an oral TPO-RA (hetrombopag or eltrombopag) that was discontinued due to insufficient response
  • Platelet count < 30 × 10⁹/L at screening, OR platelet count < 50 × 10⁹/L with concurrent clinically significant bleeding
  • Stable glucocorticoid dose (e.g., prednisone or methylprednisolone, not exceeding 4 tablets daily) for at least 2 weeks, and stable dosing of any other immunosuppressants for at least 4 weeks prior to enrollment
  • No receipt of intravenous immunoglobulin within 2 weeks before the first dose of study treatment
  • No platelet transfusion within 1 week before the first dose of study treatment

Ki nem vehet részt

  • Secondary ITP due to underlying conditions such as other autoimmune disorders, viral infections, or drug exposure
  • Presence of active malignancy, pregnancy, significant cardiovascular or cerebrovascular disease, or history of arterial/venous thrombosis

Helyszínek itt: Kína

  • The First Affiliated Hospital of Soochow UniversitySuzhou, KínaContact: Hong TianRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this trial is to assess the efficacy and safety of combining Romiplostim N01 with Rituximab for the treatment of adult patients with primary immune thrombocytopenia (ITP) whose disease is refractory to oral TPO-RAs.

A teljes eredeti leírásKevesebb

All participants in this study will receive the same combination treatment:

Rituximab: Given once a week through an intravenous infusion for 4 weeks. Romiplostim N01: Given as a weekly injection,the dose may be adjusted each week based on the patient's platelet count.

Participants will be asked to:

Visit the clinic regularly for check-ups, blood tests (to monitor platelet counts), and safety assessments.

Report their bleeding symptoms for evaluation. This is an open-label, single-arm trial, meaning that all participants will receive the investigational treatment, and both the research team and participants will be aware of the treatment assigned. The study aims to enroll approximately 30 adult patients aged 14 years or older who have been diagnosed with ITP and have not responded adequately to prior oral TPO-RAs (eltrombopag/hetrombopag).

A vizsgálat csoportja

  • Romiplostim N01 + Rituximab Combination TherapyA vizsgált kezelés

    Kezelés: Romiplostim N01 és Rituximab

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-label, Single-arm, Single-center Study to Evaluate the Efficacy and Safety of Romiplostim N01 in Combination With Rituximab in Patients With Primary Immune Thrombocytopenia Refractory to Oral TPO-RAs
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. december 4.